The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
Open accessAbstract
This review is an updated and expanded version of the five prior reviews that were published in this journal in 1997, 2003, 2007, 2012, and 2016. For all approved therapeutic agents, the time frame has been extended to cover the almost 39 years from the first of January 1981 to the 30th of September 2019 for all diseases worldwide and from ∼1946 (earliest so far identified) to the 30th of September 2019 for all approved antitumor drugs worldwide. As in earlier reviews, only the first approval of any drug is counted, irrespective of how many "biosimilars" or added approvals were subsequently identified. As in the 2012 and 2016 reviews, we have continued to utilize our secondary subdivision of a "natural product mimic", or "NM", to join the original primary divisions, and the designation "natural product botanical", or "NB", to cover those botanical "defined mixtures" now recognized as drug entities by the FDA (and similar organizations). From the data presented in this review, the utilization of natural products and/or synthetic variations using their novel structures, in order to discover and develop the final drug entity, is still alive and well. For example, in the area of cancer, over the time frame from 1946 to 1980, of the 75 small molecules, 40, or 53.3%, are N or ND. In the 1981 to date time frame the equivalent figures for the N* compounds of the 185 small molecules are 62, or 33.5%, though to these can be added the 58 S* and S*/NMs, bringing the figure to 64.9%. In other areas, the influence of natural product structures is quite marked with, as expected from prior information, the anti-infective area being dependent on natural products and their structures, though as can be seen in the review there are still disease areas (shown in Table 2) for which there are no drugs derived from natural products. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are still able to identify only two de novo combinatorial compounds (one of which is a little speculative) approved as drugs in this 39-year time frame, though there is also one drug that was developed using the "fragment-binding methodology" and approved in 2012. We have also added a discussion of candidate drug entities currently in clinical trials as "warheads" and some very interesting preliminary reports on sources of novel antibiotics from Nature due to the absolute requirement for new agents to combat plasmid-borne resistance genes now in the general populace. We continue to draw the attention of readers to the recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated"; thus we consider that this area of natural product research should be expanded significantly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This diversity of plants and secondary metabolites present in these plants indicates tremendous possibilities for drug discovery and development [3,4].”
From Yellow Himalayan Raspberry (Rubus ellipticus Sm.): Ethnomedicinal, Nutraceutical, and Pharmacological Aspects (2023) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
Natural products as sources of new drugs from 1981 to 2014
Newman, D. J., & Cragg, G. M. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b01055 · Cited by 5,858
Self-citationNatural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
Self-citationLiu, Y.-Y., Wang, Y., Walsh, T. R., Yi, L.-X., Zhang, R., Spencer, J., Doi, Y., Tian, G., Dong, B., Huang, X., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00424-7 · Cited by 5,398
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
Self-citationNatural products as sources of new drugs over the period 1981–2002
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082
Self-citationNatural products: A continuing source of novel drug leads
Cragg, G. M., & Newman, D. J. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.02.008 · Cited by 2,906
Self-citationA new antibiotic kills pathogens without detectable resistance
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., Mueller, A., Schäberle, T. F., Hughes, D. E., Epstein, S., et al. (2015) · Nature · doi:10.1038/nature14098 · Cited by 2,428
Natural Products in Drug Discovery and Development
Cragg, G. M., Newman, D. J., & Snader, K. M. (1997) · Journal of Natural Products · doi:10.1021/np9604893 · Cited by 1,585
Self-citationMartindale: The Complete Drug Reference
O’Rourke, A. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/br090004 · Cited by 1,190
Kinase inhibitors: the road ahead
Ferguson, F. M., & Gray, N. S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.21 · Cited by 1,009
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
The pharmacological basis of therapeutics
Lasagna, L. C. (1955) · Journal of Chronic Diseases · doi:10.1016/0021-9681(55)90144-2 · Cited by 754
A new antibiotic selectively kills Gram-negative pathogens
Imai, Y., Meyer, K. J., Iinishi, A., Favre-Godal, Q., Green, R., Manuse, S., Caboni, M., Mori, M., Niles, S., Ghiglieri, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1791-1 · Cited by 743
Carroll, L. M., Gaballa, A., Guldimann, C., Sullivan, G., Henderson, L. O., & Wiedmann, M. (2019) · mBio · doi:10.1128/mbio.00853-19 · Cited by 506
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Beyond the Rule of 5: Lessons Learned from AbbVie’s Drugs and Compound Collection: Miniperspective
DeGoey, D. A., Chen, H.-J., Cox, P. B., & Wendt, M. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00717 · Cited by 378
Optimized arylomycins are a new class of Gram-negative antibiotics
Smith, P. A., Koehler, M. F. T., Girgis, H. S., Yan, D., Chen, Y., Chen, Y., Crawford, J. J., Durk, M. R., Higuchi, R. I., Kang, J., et al. (2018) · Nature · doi:10.1038/s41586-018-0483-6 · Cited by 355
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
Palomo, J. M. (2014) · RSC Adv. · doi:10.1039/c4ra02458c · Cited by 273
Critical review of the role of HTS in drug discovery
Macarron, R. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.02.001 · Cited by 241
HELLMANN, K. (1968) · Nature · doi:10.1038/220308a0 · Cited by 222
Elgersma, R. C., Coumans, R. G. E., Huijbregts, T., Menge, W. M. P. B., Joosten, J. A. F., Spijker, H. J., de Groot, F. M. H., van der Lee, M. M. C., Ubink, R., van den Dobbelsteen, D. J., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500781a · Cited by 221
Kicska, G. A., Long, L., Hörig, H., Fairchild, C., Tyler, P. C., Furneaux, R. H., Schramm, V. L., & Kaufman, H. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071050798 · Cited by 192
Cheminformatic comparison of approved drugs from natural product versus synthetic origins
Stratton, C. F., Newman, D. J., & Tan, D. S. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.014 · Cited by 191
Self-citationStone, R. M., Manley, P. W., Larson, R. A., & Capdeville, R. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017011080 · Cited by 163
Drugs and Drug Candidates from Marine Sources: An Assessment of the Current “State of Play”
Newman, D., & Cragg, G. (2016) · Planta Medica · doi:10.1055/s-0042-101353 · Cited by 159
Self-citationBeyond malaria: The inhibition of viruses by artemisinin-type compounds
Efferth, T. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.01.001 · Cited by 157
Niederhuber, J. E. (1993) · B.C. Decker eBooks · Cited by 151
Le, P., Kunold, E., Macsics, R., Rox, K., Jennings, M. C., Uǧur, İ., Reinecke, M., Chaves‐Moreno, D., Hackl, M. W., Fetzer, C., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0378-7 · Cited by 145
Zarins-Tutt, J. S., Barberi, T. T., Gao, H. C., Mearns-Spragg, A., Zhang, L., Newman, D. J., & Goss, R. J. M. (2015) · Natural Product Reports · doi:10.1039/c5np00111k · Cited by 134
Self-citationCharacterization of the Chemical Space of Known and Readily Obtainable Natural Products
Chen, Y., de Lomana, M. G., Friedrich, N., & Kirchmair, J. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00302 · Cited by 118
Ataluren: First Global Approval
Ryan, N. J. (2014) · Drugs · doi:10.1007/s40265-014-0287-4 · Cited by 112
Mehran, N. A., Sinha, S., & Razeghinejad, R. (2019) · Eye · doi:10.1038/s41433-019-0671-0 · Cited by 102
Scalable Access to Arylomycins via C–H Functionalization Logic
Peters, D. S., Romesberg, F. E., & Baran, P. S. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b00087 · Cited by 101
Thorkildsen, C., Neve, S., Larsen, B. D., Meier, E., & Petersen, J. S. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.051987 · Cited by 99
Endophytic and epiphytic microbes as “sources” of bioactive agents
Newman, D. J., & Cragg, G. M. L. (2015) · Frontiers in Chemistry · doi:10.3389/fchem.2015.00034 · Cited by 98
Self-citationThe prodrug approach in the era of drug design
Najjar, A., & Karaman, R. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1553954 · Cited by 98
Pisarski, K. (2019) · Tropical Medicine and Infectious Disease · doi:10.3390/tropicalmed4010044 · Cited by 98
Natural product-like chemical space: search for chemical dissectors of macromolecular interactions
Reayi, A., & Arya, P. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.04.007 · Cited by 95
Discovery and optimization of peptide macrocycles
White, A. M., & Craik, D. J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1245720 · Cited by 83
IncP Plasmid Carrying Colistin Resistance Gene mcr-1 in Klebsiella pneumoniae from Hospital Sewage
Zhao, F., Feng, Y., Lu, X., McNally, A., & Zong, Z. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02229-16 · Cited by 81
Current Status of Marine-Derived Compounds as Warheads in Anti-Tumor Drug Candidates
Newman, D. M., & Cragg, G. M. L. (2017) · Marine Drugs · doi:10.3390/md15040099 · Cited by 75
Self-citationSodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
Beitelshees, A. L., Leslie, B. R., & Taylor, S. I. (2019) · Diabetes · doi:10.2337/dbi18-0006 · Cited by 74
Newman, D. J., & Cragg, G. M. L. (2020) · Planta Medica · doi:10.1055/a-1095-1111 · Cited by 71
Self-citationGrimshaw, C. E., Jennings, A. J., Kamran, R., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157509 · Cited by 63
Laraia, L., & Waldmann, H. (2017) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2017.03.003 · Cited by 63
Dyckman, A. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01575 · Cited by 62
Impagnatiello, F., Bastia, E., Almirante, N., Brambilla, S., Duquesroix, B., Kothe, A. C., & Bergamini, M. V. W. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14328 · Cited by 62
Bioactive Compound Collections: From Design to Target Identification
Laraia, L., Robke, L., & Waldmann, H. (2018) · Chem · doi:10.1016/j.chempr.2018.01.012 · Cited by 61
Machado, D., Antunes, J., Simões, A., Perdigão, J., Couto, I., McCusker, M. P., Martins, M., Portugal, I., Pacheco, T., Batista, J., et al. (2018) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000741 · Cited by 55
The “Utility” of Highly Toxic Marine-Sourced Compounds
Newman, D. J. (2019) · Marine Drugs · doi:10.3390/md17060324 · Cited by 49
Self-citationBiosynthetic medicinal chemistry of natural product drugs
Koehn, F. E. (2012) · MedChemComm · doi:10.1039/c2md00316c · Cited by 48
The year's new drugs & biologics - 2009
Graul, A. I., Sorbera, L. A., Pina, P., Tell, M., Cruces, E., Rosa, E., Stringer, M., Castaner, R. M., & Revel, L. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.1.1440373 · Cited by 48
Hegde, S. G., & Schmidt, M. A. (2005) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(05)40029-9 · Cited by 45
Zong, Y., Fang, F., Meyer, K. J., Wang, L., Ni, Z., Gao, H., Lewis, K., Zhang, J., & Rao, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-11211-y · Cited by 42
Screening and identification of novel biologically active natural compounds
Newman, D. J. (2017) · F1000Research · doi:10.12688/f1000research.11221.1 · Cited by 41
Self-citationPredominately Uncultured Microbes as Sources of Bioactive Agents
Newman, D. J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01832 · Cited by 40
Self-citationRational Design of Doravirine: From Bench to Patients
Hwang, C. K., Lai, M., & Hazuda, D. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00178 · Cited by 39
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2012) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-396492-2.00031-x · Cited by 33
Dantas, R. F., Evangelista, T. C. S., Neves, B. J., Senger, M. R., Andrade, C. H., Ferreira, S. B., & Silva, F. P. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1654453 · Cited by 32
Cameron, K. O., Lefker, B. A., Ke, H. Z., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.01.059 · Cited by 31
Yang, G.-R., Zhao, X.-L., Jin, F., Shi, L.-H., & Yang, J.-K. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.386 · Cited by 29
Chapter 28. To market, to market — 2000
Gaudillière, B., Bernardelli, P., & Berna, P. P. (2001) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(01)36068-2 · Cited by 29
Guided by Evolution: Biology-Oriented Synthesis of Bioactive Compound Classes
Karageorgis, G., & Waldmann, H. (2018) · Synthesis · doi:10.1055/s-0037-1610368 · Cited by 29
Macrolactamization Approaches to Arylomycin Antibiotics Core
Lim, N., Linghu, X., Wong, N. W. Y., Zhang, H., Sowell, C. G., & Gosselin, F. (2018) · Organic Letters · doi:10.1021/acs.orglett.8b03603 · Cited by 28
Chapter 26. To market, to market - 2001
Bernardelli, P., Gaudillière, B., & Vergne, F. (2002) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(02)37027-1 · Cited by 26
Natural Product Screening Reveals Naphthoquinone Complex I Bypass Factors
Vafai, S. B., Mevers, E. E., Higgins, K. W., Fomina, Y. Y., Zhang, J., Mandinova, A., Newman, D. J., Shaw, S. Y., Clardy, J., & Mootha, V. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162686 · Cited by 26
Self-citationHegde, S. G., & Schmidt, M. A. (2006) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(06)41030-7 · Cited by 25
Wang, Y., Lou, Y., Wang, J., Li, D., Chen, H., Zheng, T.-N., Xia, C., Song, X., Dong, T., Li, J., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.032 · Cited by 25
Chapter 33. To market, to market - 2002
Boyer-Joubert, C., Lorthiois, E., & Moreau, F. (2003) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(03)38034-0 · Cited by 23
Inhibition of Protein Secretion in Escherichia coli and Sub-MIC Effects of Arylomycin Antibiotics
Walsh, S. I., Peters, D. S., Smith, P. A., Craney, A. R., Dix, M. M., Cravatt, B. F., & Romesberg, F. E. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01253-18 · Cited by 23
Bronson, J. J., Dhar, T. G. M., Ewing, W. R., & Lönberg, N. (2011) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-386009-5.00002-3 · Cited by 22
Unique binding mode of Evogliptin with human dipeptidyl peptidase IV
Lee, H. K., Kim, M., Kim, H. D., Kim, H. J., Kim, J. W., Lee, J., Kim, C., & Kim, E. E. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.101 · Cited by 22
Natural Products as Sources of Anticancer Agents: Current Approaches and Perspectives
Cragg, G. M. L., & Newman, D. J. (2018) · Springer eBooks · doi:10.1007/978-3-030-00545-0_8 · Cited by 22
Self-citationHegde, S. G., & Schmidt, M. A. (2008) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)00025-0 · Cited by 21
The Year's New Drugs & Biologics, 2013: Part I
Graul, A., Cruces, E., & Stringer, M. (2014) · Drugs of today · doi:10.1358/dot.2014.50.1.2116673 · Cited by 21
Bioactive Macrocycles from Nature
Newman, D. J., & Cragg, G. M. L. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623113-00001 · Cited by 20
Self-citationBronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2013) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-417150-3.00028-4 · Cited by 18
Chapter 34. To Market, To Market – 1992
Strupczewski, J. D., & Ellis, D. B. (1993) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60904-5 · Cited by 18
Chapter 31. To Market, To Market - 1990
Strupczewski, J. D., Ellis, D. B., & Allen, R. C. (1991) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61218-x · Cited by 18
Chapter 31. To Market, To Market - 1996
Galatsis, P. (1997) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61489-x · Cited by 17
The year's new drugs & biologics, 2010
Graul, A., & Cruces, E. (2011) · Drugs of today · doi:10.1358/dot.2011.47.1.1587820 · Cited by 17
Chapter 33. To Market, To Market - 1991
Strupczewski, J. D., & Ellis, D. B. (1992) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60431-5 · Cited by 16
Chapter 32 To Market, To Market – 2006
Hegde, S. G., & Schmidt, M. A. (2007) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(07)42032-2 · Cited by 15
Chapter 31. To Market, To Market -1988
Ong, H. H., & Allen, R. C. (1989) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60553-9 · Cited by 15
Chapter 28 To Market, To Market — 2008
Hegde, S. G., & Schmidt, M. A. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04428-5 · Cited by 14
The year's new drugs & biologics, 2013: Part II
Graul, A. I., Navarro, D., Dulsat, C., et al. (2014) · Drugs of today · doi:10.1358/dot.2014.50.2.2122810 · Cited by 14
The year's new drugs and biologics, 2014: Part I
Graul, A., Cruces, E., & Stringer, M. D. (2015) · Drugs of today · doi:10.1358/dot.2015.51.1.2279964 · Cited by 14
Galatsis, P. (1998) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61097-0 · Cited by 14
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
Rendell, M. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s144556 · Cited by 14
Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 13
The Year's New Drugs & Biologics, 2011
Graul, A., Cruces, E., Dulsat, C., et al. (2012) · Drugs of today · doi:10.1358/dot.2012.48.1.1769676 · Cited by 13
The year's new drugs & biologics - 2008
Graul, A. I., Revel, L., Barrionuevo, M., Cruces, E., Rosa, E., Verges, C., Lupone, B., Diaz, N., & Castaner, R. M. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.1.1303754 · Cited by 12
Chapter 33. To Market, To Market – 1987
Ong, H. H., & Allen, R. C. (1988) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60861-1 · Cited by 12
Nature Inspired Small Molecules for Chemical Biology
Kumar, K., & Waldmann, H. (2018) · Israel Journal of Chemistry · doi:10.1002/ijch.201800105 · Cited by 11
Chapter 31. To Market, To Market - 1983
Allen, R. C. (1984) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60707-1 · Cited by 10
Chapter 33. To Market, To Market - 1989
Ong, H. H., & Allen, R. C. (1990) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61609-7 · Cited by 8
Bronson, J. J., Peese, K. M., Black, A., et al. (2015) · Medicinal chemistry reviews · doi:10.29200/acsmedchemrev-v50.ch19 · Cited by 8
Newman, D. J. (2018) · Frontiers in Marine Science · doi:10.3389/fmars.2018.00401 · Cited by 8
Self-citationBioactive Compounds from Extremophilic Marine Fungi
Giddings, L., & Newman, D. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-19030-9_18 · Cited by 7
Self-citationChapter 31. To Market, To Market - 1985
Allen, R. C. (1986) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61141-0 · Cited by 6
Chapter 31 To Market, To Market - 1986
Allen, R. C. (1987) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)61179-3 · Cited by 6
Cited by
antiSMASH 6.0: improving cluster detection and comparison capabilities
Blin, K., Shaw, S., Kloosterman, A. M., Charlop-Powers, Z., van Wezel, G. P., Medema, M. H., & Weber, T. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab335 · Cited by 2,562
Blin, K., Shaw, S., Augustijn, H. E., Reitz, Z. L., Biermann, F., Alanjary, M., Fetter, A., Terlouw, B. R., Metcalf, W. W., Helfrich, E. J. N., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad344 · Cited by 2,290
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Marshall, C. M., Federice, J. G., Bell, C. N., Cox, P. B., & Njardarson, J. T. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01122 · Cited by 1,064
Blin, K., Shaw, S., Vader, L., Szenei, J., Reitz, Z. L., Augustijn, H. E., Cediel-Becerra, J. D. D., de Crécy-Lagard, V., Koetsier, R. A., Williams, S. E., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf334 · Cited by 671
Metadata
- Authors
- Newman, D. J., & Cragg, G. M.
- Venue
- Journal of Natural Products
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-12
- Volume
- 83
- Issue
- 3
- Pages
- 770-803
- ISSN
- 0163-3864 (ISSN-L)
- 1520-6025
- OpenAlex
- W3011366455
- Cited by
- 7,015
- References
- 104
- FWCI
- 388.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.